Editorial: The mechanism of immune cells in the development of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC).

Edda Russo,Kai Yin,Xiumei Sheng,Fei Mao,Amedeo Amedei

DOI: https://doi.org/10.3389/fimmu.2023.1218958

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 19 May 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1218958

What problem does this paper attempt to address?

Editorial: Immunometabolism in autoimmune and autoinflammatory disorders

Fang Zheng,Geert Raes,Geert Raes,Shemin Lu,Qian Chen

DOI: https://doi.org/10.3389/fimmu.2023.1285720

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 01 November 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1285720
Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Wei Wu,Feidi Chen,Zhanju Liu,Yingzi Cong

DOI: https://doi.org/10.1097/MIB.0000000000000775

2016-01-01

Inflammatory Bowel Diseases

Abstract:Multiple mechanisms are involved in regulation of host response to microbiota to maintain the intestinal homeostasis. Th17 cells are enriched in the intestinal lamina propria under steady conditions. Many studies have demonstrated that microbiota-reactive Th17 cells in the intestines mediate the pathogenesis of inflammatory bowel diseases. However, clinical trials of anti-interleukin-17A or anti-interleukin-17RA antibodies in patients with Crohn's Disease show no improvement or even exacerbation of disease. Accumulating data has also indicated that Th17 cells may provide a protective effect as well to the intestines from inflammatory insults under homeostasis regulation, even under inflammatory conditions. Thus both proinflammatory and anti-inflammatory functions of intestinal Th17 cells have emerged under various conditions. In this review article, we will summarize recent progresses of Th17 cells in regulation of intestinal homeostasis and in the pathogenesis of inflammatory bowel diseases.
Editorial: Myeloid-derived suppressor cells in inflammation and its complications and cancers.

Xing Li,Dinesh Kumar Ahirwar,Xiang-Yuan Wu

DOI: https://doi.org/10.3389/fimmu.2023.1240415

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 18 July 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1240415
Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation

M Zaeem Cader,Arthur Kaser

DOI: https://doi.org/10.1136/gutjnl-2012-303955

IF: 24.5

Gut

Abstract:The intestine and its immune system have evolved to meet the extraordinary task of maintaining tolerance to the largest, most complex and diverse microbial commensal habitat, while meticulously attacking and containing even minute numbers of occasionally incoming pathogens. While our understanding is still far from complete, recent studies have provided exciting novel insights into the complex interplay of the many distinct intestinal immune cell types as well as the discovery of entirely new cell subsets. These studies have also revealed how proper development and function of the intestinal immune system is dependent on its specific microbiota, which appears to have evolutionarily co-evolved. Here we review key immune cells that maintain intestinal homeostasis and, conversely, describe how altered function and imbalances may lead to inflammatory bowel disease (IBD). We highlight the latest developments within this field, covering the major players in IBD including intestinal epithelial cells, macrophages, dendritic cells, adaptive immune cells, and the newly discovered innate lymphoid cells, which appear of characteristic importance for immune function at mucosal surfaces. We set these mucosal immune pathways in the functional context of IBD risk genes where such insight is available. Moreover, we frame our discussion of fundamental biological pathways that have been elucidated in model systems in the context of results from clinical trials in IBD that targeted key mediators secreted by these cells, as an attempt of 'functional' appraisal of these pathways in human disease.
The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms

Sofía Frigerio,Dalia A Lartey,Geert R D'Haens,Joep Grootjans

DOI: https://doi.org/10.3390/ijms222312739

2021-11-25

Abstract:Patients with inflammatory bowel disease (IBD) have increased incidence of colorectal cancer (CRC). IBD-associated cancer follows a well-characterized sequence of intestinal epithelial changes, in which genetic mutations and molecular aberrations play a key role. IBD-associated cancer develops against a background of chronic inflammation and pro-inflammatory immune cells, and their products contribute to cancer development and progression. In recent years, the effect of the immunosuppressive microenvironment in cancer development and progression has gained more attention, mainly because of the unprecedented anti-tumor effects of immune checkpoint inhibitors in selected groups of patients. Even though IBD-associated cancer develops in the background of chronic inflammation which is associated with activation of endogenous anti-inflammatory or suppressive mechanisms, the potential role of an immunosuppressive microenvironment in these cancers is largely unknown. In this review, we outline the role of the immune system in promoting cancer development in chronic inflammatory diseases such as IBD, with a specific focus on the anti-inflammatory mechanisms and suppressive immune cells that may play a role in IBD-associated tumorigenesis.
Editorial: IL-27 in Health and Disease

Tomozumi Imamichi,Xue-Feng Bai,Cory Robinson,Katrina Gee

DOI: https://doi.org/10.3389/fimmu.2023.1191228

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 31 March 2023Sec. Cytokines and Soluble Mediators in Immunity Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1191228
Interaction between diet and genetics in patients with inflammatory bowel disease

Daniéla Oliveira Magro,Ligia Yukie Sassaki,Júlio Maria Fonseca Chebli

DOI: https://doi.org/10.3748/wjg.v30.i12.1644

IF: 5.374

2024-03-28

World Journal of Gastroenterology

Abstract:In this editorial, we comment on the article by Marangoni et al , published in the recent issue of the World Journal of Gastroenterology 2023; 29: 5618-5629, about “Diet as an epigenetic factor in inflammatory bowel disease”. The authors emphasized the role of diet, especially the interaction with genetics, in promoting the inflammatory process in inflammatory bowel disease (IBD) patients, focusing on DNA methylation, histone modifications, and the influence of microRNAs. In this editorial, we explore the interaction between genetics, gut microbiota, and diet, in an only way. Furthermore, we provided dietary recommendations for patients with IBD. The Western diet, characterized by a low fiber content and deficiency the micronutrients, impacts short-chain fatty acids production and may be related to the pathogenesis of IBD. On the other hand, the consumption of the Mediterranean diet and dietary fibers are associated with reduced risk of IBD flares, particularly in Crohn’s disease (CD) patients. According to the dietary guidance from the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD), the regular consumption of fruits and vegetables while reducing the consumption of saturated, trans, dairy fat, additives, processed foods rich in maltodextrins, and artificial sweeteners containing sucralose or saccharine is recommended to CD patients. For patients with ulcerative colitis, the IOIBD recommends the increased intake of natural sources of omega-3 fatty acids and follows the same restrictive recommendations aimed at CD patients, with the possible inclusion of red meats. In conclusion, IBD is a complex and heterogeneous disease, and future studies are needed to elucidate the influence of epigenetics on diet and microbiota in IBD patients.

gastroenterology & hepatology
Dietary Regulation of the Crosstalk between Gut Microbiome and Immune Response in Inflammatory Bowel Disease

Qianqian Yao,Huiying Li,Linlin Fan,Yangdong Zhang,Shengguo Zhao,Nan Zheng,Jiaqi Wang

DOI: https://doi.org/10.3390/foods10020368

IF: 5.2

2021-02-08

Foods

Abstract:Inflammatory bowel disease (IBD), a chronic, recurring inflammatory response, is a growing global public health issue. It results from the aberrant crosstalk among environmental factors, gut microbiota, the immune system, and host genetics, with microbiota serving as the core of communication for differently-sourced signals. In the susceptible host, dysbiosis, characterized by the bloom of facultative anaerobic bacteria and the decline of community diversity and balance, can trigger an aberrant immune response that leads to reduced tolerance against commensal microbiota. In IBD, such dysbiosis has been profoundly proven in animal models, as well as clinic data analysis; however, it has not yet been conclusively ascertained whether dysbiosis actually promotes the disease or is simply a consequence of the inflammatory disorder. Better insight into the complex network of interactions between food, the intestinal microbiome, and host immune response will, therefore, contribute significantly to the diagnosis, treatment, and management of IBD. In this article, we review the ways in which the mutualistic circle of dietary nutrients, gut microbiota, and the immune system becomes anomalous during the IBD process, and discuss the roles of bacterial factors in shaping the intestinal inflammatory barrier and adjusting immune capacity.

food science & technology
New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease

Mingxia Zhou,Jing He,Yujie Shen,Cong Zhang,Jiazheng Wang,Yingwei Chen

DOI: https://doi.org/10.1155/2017/8201672

2017-01-01

BioMed Research International

Abstract:Inflammatory bowel disease (IBD), which encompasses ulcerative colitis (UC) and Crohn’s disease (CD), is a complicated, uncontrolled, and multifactorial disorder characterized by chronic, relapsing, or progressive inflammatory conditions that may involve the entire gastrointestinal tract. The protracted nature has imposed enormous economic burdens on patients with IBD, and the treatment is far from optimal due to the currently limited comprehension of IBD pathogenesis. In spite of the exact etiology still remaining an enigma, four identified components, including personal genetic susceptibility, external environment, internal gut microbiota, and the host immune response, are responsible for IBD pathogenesis, and compelling evidence has suggested that IBD may be triggered by aberrant and continuing immune responses to gut microbiota in genetically susceptibility individuals. The past decade has witnessed the flourishing of research on genetics, gut microbiota, and immunity in patients with IBD. Therefore, in this review, we will comprehensively exhibit a series of novel findings and update the major advances regarding these three fields. Undoubtedly, these novel findings have opened a new horizon and shed bright light on the causality research of IBD.
Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease

Angela Saez,Raquel Gomez-Bris,Beatriz Herrero-Fernandez,Claudia Mingorance,Cristina Rius,Jose M Gonzalez-Granado

DOI: https://doi.org/10.3390/ijms22147618

2021-07-16

Abstract:Inflammatory bowel disease (IBD) is a heterogeneous state of chronic intestinal inflammation of unknown cause encompassing Crohn's disease (CD) and ulcerative colitis (UC). IBD has been linked to genetic and environmental factors, microbiota dysbiosis, exacerbated innate and adaptive immunity and epithelial intestinal barrier dysfunction. IBD is classically associated with gut accumulation of proinflammatory Th1 and Th17 cells accompanied by insufficient Treg numbers and Tr1 immune suppression. Inflammatory T cells guide innate cells to perpetuate a constant hypersensitivity to microbial antigens, tissue injury and chronic intestinal inflammation. Recent studies of intestinal mucosal homeostasis and IBD suggest involvement of innate lymphoid cells (ILCs). These lymphoid-origin cells are innate counterparts of T cells but lack the antigen receptors expressed on B and T cells. ILCs play important roles in the first line of antimicrobial defense and contribute to organ development, tissue protection and regeneration, and mucosal homeostasis by maintaining the balance between antipathogen immunity and commensal tolerance. Intestinal homeostasis requires strict regulation of the quantity and activity of local ILC subpopulations. Recent studies demonstrated that changes to ILCs during IBD contribute to disease development. A better understanding of ILC behavior in gastrointestinal homeostasis and inflammation will provide valuable insights into new approaches to IBD treatment. This review summarizes recent research into ILCs in intestinal homeostasis and the latest advances in the understanding of the role of ILCs in IBD, with particular emphasis on the interaction between microbiota and ILC populations and functions.
Immunopathogenesis of IBD: current state of the art

Heitor S. P. de Souza,Claudio Fiocchi

DOI: https://doi.org/10.1038/nrgastro.2015.186

2015-12-02

Abstract:Key PointsSubstantial progress has been made in the understanding of IBD immunopathogenesis during the past few decadesDiscovery of the cellular and molecular mediators of intestinal inflammation has led to the development of new therapies that clearly have benefited patients with IBDEnvironmental, genetic and microbial factors interact with the immune system, resulting in dysregulated immune responses responsible for chronic intestinal inflammation typical of Crohn's disease and ulcerative colitisIBD pathogenesis also includes the effects of other cells involved in the inflammatory processes (such as epithelial, endothelial, mesenchymal and fat cells), as well as other components (such as the inflammasome and regulatory RNAs)Immunopathogenic events are only one component of IBD and they must be interpreted in the context of the other components; that is, the environment, genome and microbiotaOnly the functional integration of all the underlying components will lead to a full understanding and cure of IBD

gastroenterology & hepatology
ILC3 Function As a Double-Edged Sword in Inflammatory Bowel Diseases

Boning Zeng,Shengnan Shi,Gareth Ashworth,Changjiang Dong,Jing Liu,Feiyue Xing

DOI: https://doi.org/10.1038/s41419-019-1540-2

2019-01-01

Cell Death and Disease

Abstract:Inflammatory bowel diseases (IBD), composed mainly of Crohn’s disease (CD) and ulcerative colitis (UC), are strongly implicated in the development of intestinal inflammation lesions. Its exact etiology and pathogenesis are still undetermined. Recently accumulating evidence supports that group 3 innate lymphoid cells (ILC3) are responsible for gastrointestinal mucosal homeostasis through moderate generation of IL-22, IL-17, and GM-CSF in the physiological state. ILC3 contribute to the progression and aggravation of IBD while both IL-22 and IL-17, along with IFN-γ, are overexpressed by the dysregulation of NCR− ILC3 or NCR+ ILC3 function and the bias of NCR+ ILC3 towards ILC1 as well as regulatory ILC dysfunction in the pathological state. Herein, we feature the group 3 innate lymphoid cells’ development, biological function, maintenance of gut homeostasis, mediation of IBD occurrence, and potential application to IBD therapy.
Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology

Yue Yin,Jian Wan,Jingmin Yu,Kaichun Wu

DOI: https://doi.org/10.1093/ibd/izad081

2023-10-03

Abstract:Patients with inflammatory bowel disease (IBD) have a high risk for colorectal cancer (CRC). This cancer type, which is strongly associated with chronic inflammation, is called colitis-associated CRC (CAC). Understanding the molecular pathogenesis of CAC is crucial to identify biomarkers necessary for early diagnosis and more effective treatment directions. The accumulation of immune cells and inflammatory factors, which constitute a complex chronic inflammatory environment in the intestinal mucosa, may cause oxidative stress or DNA damage to the epithelial cells, leading to CAC development and progression. An important feature of CAC is genetic instability, which includes chromosome instability, microsatellite instability, hypermethylation, and changes in noncoding RNAs. Furthermore, the intestinal microbiota and metabolites have a great impact on IBD and CAC. By clarifying immune, genetic, intestinal microecology, and other related pathogenesis, CAC may be more predictable and treatable.
Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics

Quan Lu,Mei-feng Yang,Yu-jie Liang,Jing Xu,Hao-ming Xu,Yu-qiang Nie,Li-sheng Wang,Jun Yao,De-feng Li

DOI: https://doi.org/10.2147/JIR.S353038

IF: 4.5

2022-01-01

Journal of Inflammation Research

Abstract:As a main digestive organ and an important immune organ, the intestine plays a vital role in resisting the invasion of potential pathogens into the body. Intestinal immune dysfunction remains important pathogenesis of inflammatory bowel disease (IBD). In this review, we explained the interactions among symbiotic flora, intestinal epithelial cells, and the immune system, clarified the operating mechanism of the intestinal immune system, and highlighted the immunological pathogenesis of IBD, with a focus on the development of immunotherapy for IBD. In addition, intestinal fibrosis is a significant complication in patients with long-term IBD, and we reviewed the immunological pathogenesis involved in the development of intestinal fibrogenesis and provided novel antifibrotic immunotherapies for IBD.
P096 Characterization of suppressive immune cell subsets in mouse models of colitis-associated colorectal cancer

S Frigerio,J Saris,R Franco Fernandez,P Koelink,M van Roest,M Wildenberg,G D'Haens,J Grootjans

DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0226

2023-01-30

Journal of Crohn's and Colitis

Abstract:Abstract Background Chronic colonic inflammation in inflammatory bowel disease (IBD) patients increases the risk of colitis-associated cancer (CAC). Cancer development in CAC is different from that observed in sporadic colorectal cancer (CRC). Most studies have focused on the role of pro-inflammatory immune cell subsets in CAC, yet it is becoming increasingly clear that immunosuppression may also drive cancer progression. We hypothesize that emergence of immunosuppressive cell subsets as a result of chronic intestinal inflammation, dampens anti-tumor immune responses and accelerates the development of CAC. Methods To simulate cancer formation in the background of chronic inflammation, mice were treated with azoxymethane (AOM) followed by three cycles of dextran sodium sulphate (DSS). Apc Min/+ mice treated with AOM were used to model sporadic CRC. After 10 weeks, immune cells from the proximal and distal colonic lamina propria, mesenteric lymph nodes (MLNs) and tumors were obtained for microscopy analyses and processed to obtain single cell suspensions for flow cytometry. Immune cell populations were studied by conventional flow cytometry and immunofluorescence. Results We observed a significant increase in absolute numbers of PD1+CTLA4+TIM3+ ‘exhausted’ CD4+ T cells in the lamina propria from proximal colons in CAC mice as compared to sporadic CRC mice. Interestingly, these numbers showed a positive correlation with the inflammation score in AOM/DSS, demonstrating that chronic inflammation is associated with the emergence of ‘exhausted’ T cells. In addition, we observed a trend to higher numbers of M2-like (MHCII-CD206+) suppressive macrophages and CD4+FoxP3+ regulatory T cells (Tregs) in tumors from CAC mice compared to sporadic CRC. When analysing T cell immune responses in the MLNs, we found a significant decrease in the ratio IFNγ/IL10-producing CD8+ T cells in CAC mice as compared to CRC mice, suggesting a shift towards an anti-inflammatory T cell response in CAC. Conclusion In summary, suppressive immune cell subsets were increased in colonic mucosa and tumors from CAC mice as a result of chronic inflammation, which may be associated with the development of dysplasia. Further functional studies are necessary to prove the role of suppressive immune subsets in IBD-associated dysplasia- and carcinoma progression.

gastroenterology & hepatology
Interplay between Cellular and Molecular Mechanisms Underlying Inflammatory Bowel Diseases Development-A Focus on Ulcerative Colitis

Iuliana Samoilă,Sorina Dinescu,Marieta Costache

DOI: https://doi.org/10.3390/cells9071647

IF: 6

2020-07-09

Cells

Abstract:Inflammatory bowel diseases (IBD) are defined by the continuous inflammation of the gastrointestinal tract. During inflammation, the number of pathogens in the intestinal epithelium increases, leading to inflammasome assembly. Inflammasome activation is meant to protect the intestinal epithelial barrier from further damage by maintaining homeostasis. Although its purpose is to protect the cells, excessive nucleotide-binding oligomerization domain-like receptor and pyrin domain-containing protein 3 (NLRP3) inflammasome assembly is responsible for the synthesis of a high number of pro-inflammatory cytokines. The activation of two crucial pathways, autophagy process, and unfolded protein response, is initiated for restoring homeostasis. Aberrant expression of miRNAs and lncRNAs also interfere with the pathogenic mechanisms of IBD, as these non-coding transcripts play key roles in regulation of biological processes, such as inflammation and immunity. This review thoroughly describes the cellular and molecular mechanism that trigger and perpetuate inflammation in ulcerative colitis (UC) patients.
Editorial: Molecular insights of microbiota and innate lymphoid cell interactions

José Luís Fachi,Marcela Davoli Ferreira,Niels Olsen Saraiva Câmara

DOI: https://doi.org/10.3389/fimmu.2024.1497305

IF: 7.3

2024-10-11

Frontiers in Immunology

Abstract:In the dynamic field of immunology, the discovery of innate lymphoid cells (ILCs) in 2008 marked a transformative milestone, as highlighted by Vivier et al. (2018). These cells, present in both humans and mice, have become central to research due to their crucial role in maintaining barrier immunity and their involvement in a range of microbiota-driven disorders.ILCs are a diverse group of cells categorized into three main subsets based on their expression of transcription factors and cytokines (Vivier et al., 2018). Group 1 ILCs (including ILC1 and NK cells) are characterized by the expression of T-bet and IFN-γ, mirroring the function of Th1 cells.Group 2 ILCs express GATA3 and cytokines such as IL-4, IL-5, and IL-13, resembling Th2 cells.Group 3 ILCs, defined by the expression of RORγt and production of are analogous to Th17 cells. Although ILCs perform functions similar to adaptive T cells, they are distinguished by the absence of antigen-specific receptors. Instead, their activation and responses are mediated through cytokine and alarmin signaling. These cells are primarily located at mucosal surfaces and other barrier sites and act as a crucial first line of defense by rapidly producing cytokines that orchestrate immune responses and maintain tissue homeostasis. Their role in health and disease is increasingly recognized, particularly in conditions such as inflammatory bowel diseases, cancer, autoimmunity, and metabolic disorders. A key aspect of their function is their interaction with the microbiota-a complex and diverse community of microorganisms essential for shaping host immunity. In particular, the gut microbiota influences immune cell development, modulates inflammatory responses, and impacts systemic immunity (Zheng et al., 2020). Positioned strategically at these barrier sites, ILCs are well-equipped to sense microbial signals and respond accordingly, helping to maintain a balanced immune environment. Disruptions in this crosstalk can lead to dysbiosis, driving the onset and progression of various diseases. Understanding these interactions holds significant potential for developing microbiota-targeted therapies that could restore immune balance and offer new approaches to disease treatment and prevention. In addition to exploring these biological interactions, the integration of multi-omics technologies and artificial intelligence (AI) has opened new avenues for investigating the complex relationships between immune cells and their environment. Xu et al. contribution within this Research Topic utilizes these advanced approaches to uncover new neutrophil clusters and potential biomarkers in sepsis, offering valuable insights into the immune landscape during severe infection. This research not only enhances our understanding of sepsis but also illustrates the potential of integrating multi-

immunology
Integration of Gut Mycobiota and Oxidative Stress to Decipher the Roles of C-Type Lectin Receptors in Inflammatory Bowel Diseases

Liu Yang,Min Hu,Jing Shao

DOI: https://doi.org/10.1080/08820139.2024.2388164

2024-08-08

Abstract:Background: Ulcerative colitis (UC) and Crohn's disease (CD) are two subtypes of inflammatory bowel disease (IBD) with rapidly increased incidence worldwide. Although multiple factors contribute to the occurrence and progression of IBD, the role of intestinal fungal species (gut mycobiota) in regulating the severity of these conditions has been increasingly recognized. C-type lectin receptors (CLRs) on hematopoietic cells, including Dectin-1, Dectin-2, Dectin-3, Mincle and DC-SIGN, are a group of pattern recognition receptors (PRRs) that primarily recognize fungi and mediate defense responses, such as oxidative stress. Recent studies have demonstrated the indispensable role of CLRs in protecting the colon from intestinal inflammation and mucosal damage. Methods and results: This review provides a comprehensive overview of the role of CLRs in the pathogenesis of IBD. Given the significant impact of mycobiota and oxidative stress in IBD, this review also discusses recent advancements in understanding how these factors exacerbate or ameliorate IBD. Furthermore, the latest developments in CLR-guided IBD therapy are examined to highlight the modulation of CLRs in fungal recognition and oxidative burst during the IBD process. Conclusion: This review emphasizes the importance of CLRs in IBD, offering new perspectives on the etiology and therapeutic approaches for this disease.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD

Anaïs Larabi,Nicolas Barnich,Hang Thi Thu Nguyen

DOI: https://doi.org/10.1080/15548627.2019.1635384

IF: 13.391

2019-07-09

Autophagy

Abstract:One of the most significant challenges of inflammatory bowel disease (IBD) research is to understand how alterations in the symbiotic relationship between the genetic composition of the host and the intestinal microbiota, under impact of specific environmental factors, lead to chronic intestinal inflammation. Genome-wide association studies, followed by functional studies, have identified a role for numerous autophagy genes in IBD, especially in Crohn disease. Studies using in vitro and in vivo models, in addition to human clinical studies have revealed that autophagy is pivotal for intestinal homeostasis maintenance, gut ecology regulation, appropriate intestinal immune responses and anti-microbial protection. This review describes the latest researches on the mechanisms by which dysfunctional autophagy leads to disrupted intestinal epithelial function, gut dysbiosis, defect in anti-microbial peptide secretion by Paneth cells, endoplasmic reticulum stress response and aberrant immune responses to pathogenic bacteria. A better understanding of the role of autophagy in IBD pathogenesis may provide better sub-classification of IBD phenotypes and novel approaches for disease management.Abbreviations: AIEC: adherent-invasive Escherichia coli; AMPK: AMP-activated protein kinase; ATF6: activating transcription factor 6; ATG: autophagy related; Atg16l1[ΔIEC] mice: mice with Atg16l1 depletion specifically in intestinal epithelial cells; Atg16l1[HM] mice: mice hypomorphic for Atg16l1 expression; BCL2: B cell leukemia/lymphoma 2; BECN1: beclin 1, autophagy related; CALCOCO2: calcium binding and coiled-coil domain 2; CASP: caspase; CD: Crohn disease; CGAS: cyclic GMP-AMP synthase; CHUK/IKKA: conserved helix-loop-helix ubiquitous kinase; CLDN2: claudin 2; DAPK1: death associated protein kinase 1; DCs: dendritic cells; DSS: dextran sulfate sodium; EIF2A: eukaryotic translation initiation factor 2A; EIF2AK: eukaryotic translation initiation factor 2 alpha kinase; ER: endoplasmic reticulum; ERBIN: Erbb2 interacting protein; ERN1/IRE1A: ER to nucleus signaling 1; FNBP1L: formin binding protein 1-like; FOXP3: forkhead box P3; GPR65: G-protein coupled receptor 65; GSK3B: glycogen synthase kinase 3 beta; IBD: inflammatory bowel disease; IECs: intestinal epithelial cells; IFN: interferon; IL: interleukin; IL10R: interleukin 10 receptor; IRGM: immunity related GTPase M; ISC: intestinal stem cell; LAMP1: lysosomal-associated membrane protein 1; LAP: LC3-associated phagocytosis; MAP1LC3B: microtubule-associated protein 1 light chain 3 beta; LPS: lipopolysaccharide; LRRK2: leucine-rich repeat kinase 2; MAPK: mitogen-activated protein kinase; MHC: major histocompatibility complex; MIF: macrophage migration inhibitory factor; MIR/miRNA: microRNA; MTMR3: myotubularin related protein 3; MTOR: mechanistic target of rapamycin kinase; MYD88: myeloid differentiation primary response gene 88; NLRP3: NLR family, pyrin domain containing 3; NOD2: nucleotide-binding oligomerization domain containing 2; NPC: Niemann-Pick disease type C; NPC1: NPC intracellular cholesterol transporter 1; OMVs: outer membrane vesicles; OPTN: optineurin; PI3K: phosphoinositide 3-kinase; PRR: pattern-recognition receptor; PTPN2: protein tyrosine phosphatase, non-receptor type 2; PTPN22: protein tyrosine phosphatase, non-receptor type 22 (lymphoid); PYCARD/ASC: PYD and CARD domain containing; RAB2A: RAB2A, member RAS oncogene family; RELA: v-rel reticuloendotheliosis viral oncogene homolog A (avian); RIPK2: receptor (TNFRSF)-interacting serine-threonine kinase 2; ROS: reactive oxygen species; SNPs: single nucleotide polymorphisms; SQSTM1: sequestosome 1; TAX1BP1: Tax1 binding protein 1; Th: T helper 1; TIRAP/TRIF: toll-interleukin 1 receptor (TIR) domain-containing adaptor protein; TLR: toll-like receptor; TMEM173/STING: transmembrane protein 173; TMEM59: transmembrane protein 59; TNF/TNFA: tumor necrosis factor; Treg: regulatory T; TREM1: triggering receptor expressed on myeloid cells 1; UC: ulcerative colitis; ULK1: unc-51 like autophagy activating kinase 1; WT: wild-type; XBP1: X-box binding protein 1; XIAP: X-linked inhibitor of apoptosis.
Editorial: Involvement of Dendritic Cells in Gastrointestinal Cancer

Lei Ni,Jingtao Chen,Mei Deng,Haidong Tang,Manzhu Bao

DOI: https://doi.org/10.3389/fimmu.2023.1178075

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 17 March 2023Sec. Cancer Immunity and Immunotherapy Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1178075

Editorial: The mechanism of immune cells in the development of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC).

Editorial: Immunometabolism in autoimmune and autoinflammatory disorders

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Editorial: Myeloid-derived suppressor cells in inflammation and its complications and cancers.

Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation

The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms

Editorial: IL-27 in Health and Disease

Interaction between diet and genetics in patients with inflammatory bowel disease

Dietary Regulation of the Crosstalk between Gut Microbiome and Immune Response in Inflammatory Bowel Disease

New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease

Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease

Immunopathogenesis of IBD: current state of the art

ILC3 Function As a Double-Edged Sword in Inflammatory Bowel Diseases

Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology

Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics

P096 Characterization of suppressive immune cell subsets in mouse models of colitis-associated colorectal cancer

Interplay between Cellular and Molecular Mechanisms Underlying Inflammatory Bowel Diseases Development-A Focus on Ulcerative Colitis

Editorial: Molecular insights of microbiota and innate lymphoid cell interactions

Integration of Gut Mycobiota and Oxidative Stress to Decipher the Roles of C-Type Lectin Receptors in Inflammatory Bowel Diseases

New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD

Editorial: Involvement of Dendritic Cells in Gastrointestinal Cancer